Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
8903 | 1138 | 32.1 | 69% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | PENTOXIFYLLINE | Author keyword | 141 | 32% | 32% | 369 |
2 | LISOFYLLINE | Author keyword | 15 | 63% | 1% | 15 |
3 | GUDE | Address | 3 | 33% | 1% | 7 |
4 | GEN VASC SURG TRANSPLANTOL | Address | 3 | 60% | 0% | 3 |
5 | PENTOXIPHYLLINE | Author keyword | 2 | 36% | 0% | 5 |
6 | PENTOXIFYLLINE PTX | Author keyword | 2 | 67% | 0% | 2 |
7 | PENTOXIFYLLINE THERAPEUTIC USE | Author keyword | 2 | 67% | 0% | 2 |
8 | G2 M BLOCK ABROGATION | Author keyword | 1 | 100% | 0% | 2 |
9 | HEMORRHEOLOGIC AGENTS | Author keyword | 1 | 50% | 0% | 2 |
10 | METABOLITE 1 | Author keyword | 1 | 100% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PENTOXIFYLLINE | 141 | 32% | 32% | 369 | Search PENTOXIFYLLINE | Search PENTOXIFYLLINE |
2 | LISOFYLLINE | 15 | 63% | 1% | 15 | Search LISOFYLLINE | Search LISOFYLLINE |
3 | PENTOXIPHYLLINE | 2 | 36% | 0% | 5 | Search PENTOXIPHYLLINE | Search PENTOXIPHYLLINE |
4 | PENTOXIFYLLINE PTX | 2 | 67% | 0% | 2 | Search PENTOXIFYLLINE+PTX | Search PENTOXIFYLLINE+PTX |
5 | PENTOXIFYLLINE THERAPEUTIC USE | 2 | 67% | 0% | 2 | Search PENTOXIFYLLINE+THERAPEUTIC+USE | Search PENTOXIFYLLINE+THERAPEUTIC+USE |
6 | G2 M BLOCK ABROGATION | 1 | 100% | 0% | 2 | Search G2+M+BLOCK+ABROGATION | Search G2+M+BLOCK+ABROGATION |
7 | HEMORRHEOLOGIC AGENTS | 1 | 50% | 0% | 2 | Search HEMORRHEOLOGIC+AGENTS | Search HEMORRHEOLOGIC+AGENTS |
8 | METABOLITE 1 | 1 | 100% | 0% | 2 | Search METABOLITE+1 | Search METABOLITE+1 |
9 | METHYLXANTHINE DERIVATIVES | 1 | 100% | 0% | 2 | Search METHYLXANTHINE+DERIVATIVES | Search METHYLXANTHINE+DERIVATIVES |
10 | PHOSPHODIESTERASE INHIBITORS THERAPEUTIC USE | 1 | 100% | 0% | 2 | Search PHOSPHODIESTERASE+INHIBITORS+THERAPEUTIC+USE | Search PHOSPHODIESTERASE+INHIBITORS+THERAPEUTIC+USE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SEPTIC GUINEA PIGS | 9 | 83% | 0% | 5 |
2 | PHOSPHATIDIC ACID GENERATION | 8 | 100% | 0% | 5 |
3 | OXPENTIFYLLINE | 5 | 27% | 1% | 15 |
4 | PHOSPHODIESTERASE INHIBITOR PENTOXIFYLLINE | 4 | 39% | 1% | 9 |
5 | PERITONITIS MODEL | 4 | 47% | 1% | 7 |
6 | PREFERENTIAL RADIOSENSITIZATION | 4 | 67% | 0% | 4 |
7 | ORAL PENTOXIFYLLINE | 3 | 43% | 1% | 6 |
8 | IMMUNOMODULATING AGENT | 3 | 60% | 0% | 3 |
9 | MURINE COLON ADENOCARCINOMA | 2 | 67% | 0% | 2 |
10 | RAT RHABDOMYOSARCOMAS | 2 | 67% | 0% | 2 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
PENTOXIFYLLINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND ITS THERAPEUTIC EFFICACY | 1987 | 601 | 126 | 66% |
PENTOXIFYLLINE | 1994 | 168 | 132 | 51% |
Immunological mechanisms of pentoxifylline in chronic heart failure | 2009 | 36 | 39 | 44% |
Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis | 2015 | 2 | 28 | 54% |
A Review of the Potential Benefits of Pentoxifylline in Diabetic and Non-Diabetic Proteinuria | 2011 | 8 | 47 | 64% |
A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity | 2013 | 6 | 65 | 48% |
Effects of phosphodiesterase inhibition on the inflammatory response after shock: Role of pentoxifylline | 2004 | 40 | 101 | 40% |
Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis | 1997 | 74 | 148 | 39% |
Pentoxifylline for diabetic kidney disease | 2012 | 5 | 54 | 43% |
Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates | 2011 | 9 | 28 | 36% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | GUDE | 3 | 33% | 0.6% | 7 |
2 | GEN VASC SURG TRANSPLANTOL | 3 | 60% | 0.3% | 3 |
3 | AGGERTALKLIN | 1 | 50% | 0.1% | 1 |
4 | ANESTHESIOL CRIT CAR | 1 | 50% | 0.1% | 1 |
5 | BIOPHARMCEUT | 1 | 50% | 0.1% | 1 |
6 | CARDIAC VASC SURG UNIT | 1 | 50% | 0.1% | 1 |
7 | CARDIO NEPHROL | 1 | 50% | 0.1% | 1 |
8 | EAR NOSE THROAT EDUC | 1 | 50% | 0.1% | 1 |
9 | NEPHRIT URINARY DIS | 1 | 50% | 0.1% | 1 |
10 | UFR MED PARIS DENIS DIDEROT 7CLAUDE BERNARD IFR0 | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000095383 | BUFLOMEDIL//CAS 55837 25 7//CENTROPHENOXINE HYDROCHLORIDE |
2 | 0.0000089848 | CLINICAL HEMORHEOLOGY//IST CLIN MED MALATTIE CARDIOVASC//VASCULAR ATHEROSCLEROTIC DISEASE |
3 | 0.0000066834 | PATHOLCARDIOVASC//RENAL PROSTANOIDS//MCGUIRE |
4 | 0.0000066516 | G2 REPAIR//CHROMATID TYPE ABERRATIONS//G2 M OVERRIDE |
5 | 0.0000062495 | L1210 CELL LINE//TCRP1//MOL PHYSIOL GENET |
6 | 0.0000054154 | HYPERVOLUMETRIC HEMODILUTION//NEUROL D4 5//HYPERVOLEMIC HEMODILUTION |
7 | 0.0000048772 | ANTI INTERFERON GAMMA//INTERFERON INHIBITORS//MECLOMEN |
8 | 0.0000045128 | 2 DEOXYADENOSINE//MOTILITY STIMULANTS//COMPUTER ASSISTED SPERM MOTION ANALYSIS |
9 | 0.0000034981 | ANKLE BRACHIAL INDEX//INTERMITTENT CLAUDICATION//PERIPHERAL ARTERIAL DISEASE |
10 | 0.0000034439 | NAFTIDROFURYL//NEBRACETAM//MICROSPHERE EMBOLISM |